All In Biotech

Free tool

FAERS Monitor: Lytgobi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214801 or its brand name (Lytgobi, Futibatinib). Reports on generic versions are filed under their own applications.

Reports

222

Serious

152

68% of reports

Hospitalization

71

Death reported

42

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea39
  • hyperphosphataemia36
  • death32
  • disease progression31
  • fatigue28
  • nausea26
  • dry mouth24
  • off label use20
  • vomiting18
  • onychomadesis17
  • blood phosphorus increased16
  • constipation16
  • dry eye16
  • neuropathy peripheral16
  • alopecia15

Reports by year received

View as table
YearReports
20213
202214
202350
202459
202557
202639

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,937 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperphosphataemiaSignal361613.51192.955,474
blood phosphorus increasedSignal16558.5347.88,307
onychomadesisSignal17385.3243.86,114
dry eyeSignal1630.418.9427
dry mouthSignal2428.019.2601
disease progressionSignal3124.817.9689
neuropathy peripheralSignal1615.99.9210
alopeciaSignal157.24.475
constipationSignal167.04.376
diarrhoeaSignal395.74.3152
vomitingSignal183.62.332
deathSignal323.52.658
fatigueSignal283.42.447
nauseaSignal263.12.237
off label useSignal202.21.412

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.